Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 109

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 109
---
 |           73 | ​ | ​ |       122 | ​ | ​ |          — |
| As adjusted (non-GAAP)                                                                                     | ​ | $         | 47,338 | ​ | $ |       24,642 | ​ | $ |    26,219 | ​ | $ |     20,705 |
| ​                                                                                                          | ​ | ​         |      ​ | ​ | ​ |            ​ | ​ | ​ |         ​ | ​ | ​ |          ​ |
| *Net revenues are adjusted as outlined in the table to calculate the Platform Revenue performance results. |   |           |        |   |   |              | ​ | ​ |         ​ | ​ | ​ |          ​ |
| **Represents net earnings attributable to AbbVie Inc.                                                      | ​ | ​         |      ​ | ​ | ​ |            ​ | ​ | ​ |         ​ | ​ | ​ |          ​ |

Intangible asset impairment reflects a partial impairment charge related to the emraclidine intangible asset acquired as part of the Cerevel Therapeutics acquisition. Acquisition and integration costs primarily reflect costs related to the ImmunoGen and Cerevel Therapeutics acquisitions. Acquired IPR&D and milestones represents initial costs and subsequent development milestones incurred to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. Income tax items primarily reflect an income tax benefit related to the settlement of income tax examinations, partially offset by changes in income tax reserves. Litigation matters primarily include charges related to actual and potential settlements of litigation .

B-2 | 2025 Proxy Statement

2023 Performance Results for Financial Goals Reconciliations

| ​                                                                                                          
 ​                                                                                                          
 ​                                                                                                          | ​ 
 ​ | ​         
 Net       
 Revenues* |       ​ | ​ 
 ​ | ​ 
 ​ 
 ​ |            ​ 
       Income 
 Before Taxes | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ |         ​ 
 Operating 
    Margin | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ |          ​ 
        Net 
 Earnings** |
|:-----------------------------------------------------------------------------------------------------------|:--|:----------|--------:|:--|:--|-------------:|:--|:--|----------:|:--|:--|-----------:|
| As reported (GAAP)                                                                                         | ​ | $         |  54,318 | ​ | $ |        6,250 | ​ | $ |